The European Commission has launched a public consultation on the definition of the term "nanomaterials" now that its Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has published a preliminary opinion on the matter1,2. The consultation aims to achieve a science-based working definition, which is viewed as critical for the development of policy and regulatory activities on nanotechnologies, including nanomedicine...
Scrip Regulatory Affairs
EU a step closer to defining nanomaterials
14 July 2010
Karen Finn; Amanda Maxwell
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- ICH to clarify E3 guideline on clinical study reports and alignment with CTD
- US FDA lays out ambitious goals for driving drug and device innovation, but funding hazy
- EU Central Management Committee weighs in on regulation of notified bodies
- EU finalises guidance on reporting adverse events from clinical trials
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
